PATH chooses Mymetics for work on transmission-blocking malaria vaccine

With a brand-new $156 million Gates Foundation grant in hand, the PATH Malaria Vaccine Initiative (MVI) has signed on Switzerland-based Mymetics to develop and produce virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate. The biotech will work alongside the Laboratory of Malaria Immunology and Vaccinology, part of the NIH's National Institute of Allergy and Infectious Diseases (NIAID), it said. Release | More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.